EDN1 and endothelial dysfunction: This study demonstrated that the antihypertensive effect of orally administered PSAE in SHRs may be due to its ability to ameliorate endothelial dysfunction by increasing the resistance artery NO level and reducing the resistance artery ET-1 level.